<< Report predicts Africa's tobacco use will double within 12 years without intervention | Hoyer: House could be in session until late December >>

Read in | English | Español | Français | Deutsch | Português | Italiano | 日本語 | 한국어 | 简体中文 | 繁體中文 | Nederlands | Русский | Svenska | Polski

Endo Pharmaceuticals reaches patent litigation settlement with LecTec

Published on November 11, 2009 at 11:48 PM · No Comments

Endo Pharmaceuticals (Nasdaq: ENDP) announced today that it has reached a settlement with LecTec Corporation on outstanding patent litigation related to LecTec's U.S. Patent Nos. 5,536,263 and 5,741,510.

Endo Pharmaceuticals has agreed to make a one-time, $23 million payment for the exclusive license to these two patents for use in the field of prescription pain medicines and treatment. "We are pleased to add these patents to our IP inventory especially as they relate to Lidoderm®," said Caroline Manogue, executive vice president and chief legal officer of Endo Pharmaceuticals.

SOURCE Endo Pharmaceuticals

0f809b82-6017-4c76-9c0b-3a2b2591ae51|0|.0

Posted in: Medical Patent News

Tags: Anti-Inflammatory, Cancer, Endocrinology, Migraine, Neuralgia, Neurology, Oncology, Osteoarthritis, Prostate Cancer, Puberty, Urology, Voltaren

Related posts

Tempo of puberty linked to anxiety, depressionChildren who go through puberty at a faster rate are more likely to act out and to suffer from anxie...
Columbia Laboratories second quarter total net revenues increase to $19.2 millionColumbia Laboratories, Inc. today reported financial results for the three- and six-month periods en...
POZEN reports revenue of $4.5 million for first quarter 2011POZEN Inc., a pharmaceutical company committed to transforming medicine that transforms lives, today...
MAKO's RIO Robotic Arm Interactive Orthopedic System receives 2010 Gold Medical Design Excellence AwardMAKO Surgical Corp. announced that its RIO® Robotic Arm Interactive Orthopedic System has received a...
Charles Sherr awarded distinction of AAAS FellowCharles Sherr, M.D., Ph.D., co-chair of Genetics and Tumor Cell Biology at St. Jude Children's Resea...
DiaMedica to acquire all issued and outstanding shares of SanomuneDiaMedica Inc. (TSX VENTURE:DMA)("Diamedica"), a biopharmaceutical company that has discovered and i...
Third-quarter 2009 financial results announced by InhibitexInhibitex, Inc., today announced its financial results for the third quarter ended September 30, 200...
Fertility Centers of Illinois offers "baby or money back" programA new study has confirmed anecdotal reports that the recession has caused a decline in fertility tre...
Upsher-Smith Laboratories publishes data on Slo-Niacin and Lipitor combination studyResults of the SLIM Study ("Slo-Niacin® and Atorvastatin Treatment of Lipoproteins and Inflammatory ...
Genspera to commence G-202 Phase I trial following FDA approvalGenSpera, Inc. announced today that the Food and Drug Administration (FDA) has approved its Investig...
Endo Pharmaceuticals launches VALSTAR for treating recurrent carcinoma in situ bladder tumorsEndo Pharmaceuticals (Nasdaq: ENDP) today announced the availability of VALSTAR(TM) (valrubicin) for...
Gene therapy to turn off Parkinson'sA group of Northwestern University researchers is developing a novel gene therapy aimed at selective...

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.

Quirky Comment Title
Name*
E-mail*
Country Country flag

b i u quote

Comment
Preview

Leave this field blank

News-Medical.Net provides this medical information service in accordance with these terms and conditions. Please note that medical information found on this website is designed to support, not to replace the relationship between patient and physician/doctor and the medical advice they may provide.